Myricetin, irreversible TrxR inhibitor (ab120721)
Key features and details
- Potent antineoplastic, antioxidant and anti-inflammatory agent
- CAS Number: 529-44-2
- Purity: > 97%
- Soluble in DMSO to 100 mM and in ethanol to 50 mM
- Form / State: Solid
- Source: Synthetic
Overview
-
Product name
Myricetin, irreversible TrxR inhibitor -
Description
Potent antineoplastic, antioxidant and anti-inflammatory agent -
Biological description
Directly inhibits MEK, JAK1, Akt and MKK4 kinase activity. Able to inhibit cytochrome P450 3A4 and 2C9 (IC50 = 7.81 and 13.5 μM, respectively).
-
Purity
> 97% -
CAS Number
529-44-2 -
Chemical structure
Images
-
Functional Studies - Myricetin, irreversible TrxR inhibitor (ab120721)
PC 12 cells were incubated at 37°C for 30 minutes with vehicle control (0 µM) and different concentrations of myricetin (ab120721). Increased expression of CaMKII (phospho T286) (ab32678) in PC 12 cells correlates with an increase in myricetin concentration, as described in literature.
Whole cell lysates were prepared with RIPA buffer (containing protease inhibitors and sodium orthovanadate), 20 µg of each were loaded on the gel and the WB was run under reducing conditions. After transfer the membrane was blocked for an hour using 3% milk before being incubated with ab32678at 1/500 dilution and ab52476 at 1/500 dilution overnight at 4°C. Antibody binding was detected using an anti-rabbit antibody conjugated to HRP (ab97051) at 1/10000 dilution and visualised using ECL development solution.
